Studies in other B-cell malignancies (lymphoma, myeloma and CLL) showed the engagement of NF-κB, MAPK, and Akt by BAFF or APRIL stimulation.[36], [37], [38] Our study unveils the involvement of new molecular axis in the biology of malignant BCP, particularly in the crosstalk between leukemia cells and their supportive BM microenvironment. The gene discussed is AKT1; the disease is plasma cell myeloma.